Shares of Discovery Labs (DSCO) have been drifting lower in recent trading and now are at the $1.55 level, which is a nice entry point for a long position for speculative biotech investors. Since meeting with the FDA in mid-June, DSCO has trended lower on investor disappointment that the Company would delay its response to the most recent approvable ruling for Surfaxin until September. However, the Company still expects a Class I review (60 days), which could result in approval for Surfaxin by late November or early December without the need for additonal clinical trials. Summer is typically a slow time for biotech trading and provides a good time to accumulate shares ahead of a Fall catalyst.

Technical picture shows Google (GOOG) shares returned back above 200 days moving average. This confirms growing trend giving nice signal to long term investors. Open long position with stop loss on level of 200 MA.Main fuel for Google share were Yahoo (YHOO) - Microsoft (MSFT) - Google (GOOG) deal news together with latest ComScore (SCOR) statistics. Numbers indicate 20% growth in paid clicks. Total clicks growth is 28%. Better than expected data includes only US clicks.It's still in our mind last ComScore report before Google's Q1. Nevertheless ComScore released slower growth for US clicks, Google posted very good Q1 results which lifted stock. Mainly due to growth outside of US.Coming back, good US paid clicks rate altogether with possible outstanding global growth. It could be good time to think about Google.http://stockweb.blogspot.com/atom.xml

...